Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01777152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01777152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Lead sponsor
Seagen Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2013
Completion date
October 2, 2020
Enrollment
452 (actual)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large-cell lymphoma, non-hodgkin lymphoma, t-cell lymphoma